AppLovin Jumps 4% as Buyers Return After Year-Long Slide; Trade Desk Nudges Higher, Digital Turbine Barely Budges

AppLovin (NASDAQ: APP) shares fell to a 52-week low after Unity's comments. The company sued Unity (NYSE: U) for alleged data misuse, seeking to block data collection. Unity denied claims, calling it a competitive tactic. AppLovin's stock is down 11.4% from its 20-day average and 39.2% from its 200-day average, trading at $282.18.

AppLovin sued Unity in California court, alleging data collection via Unity's Ad Quality SDK without permission. AppLovin claims Unity used this data to train models for ad auctions. Unity denies the claims, calling them anticompetitive. AppLovin seeks a temporary restraining order to halt data collection and modification of the SDK. Both companies have tools for ad quality control, with differing claims about their intrusiveness.

AppLovin (APP) shares fell 4.5% to a 52-week low after Wells Fargo questioned the significance of a recent spike in Pixel installs, calling it a 'false start.' Wells maintained an Equal Weight rating and $325 price target, below the street average of $500. The firm noted most new installs were low-traffic Asia-Pacific Shopify stores, suggesting a data quirk rather than meaningful e-commerce growth.

Applovin (APP) shares fell 0.5% pre-market to $304.12 after Wells Fargo reiterated its Equal Weight rating and $325 target, citing skepticism about e-commerce growth. The bank noted slow merchant website additions and low-quality traffic. Legal issues and weak market sentiment added to pressure, with the stock near its 52-week low of $297.50.

Capricor Therapeutics (CAPR) shares rose 17% after positive clinical data. Iovance Biotherapeutics (IOVA) gained 31% on raised revenue outlook. DraftKings (DKNG) fell 7% amid competitor funding news. Trade Desk (TTD) declined on revenue growth concerns. Dow is down for Q3, while S&P 500 and Nasdaq are up. PCE data release expected to impact markets.

AppLovin (APP) faces a class action lawsuit alleging misrepresentation of its AI business, with shares down 54% in 2026. Analysts have mixed views, with a mid-target price of ~$957 and potential total return of ~208%. The company reports Q3 earnings, with consensus at ~$2.07B. Legal and business risks remain.